$INSM

Flammer Martina M.D. sold $3.5M of INSM

Flammer Martina M.D. (Chief Medical Officer) sold 27,173 shares of INSMED Inc (INSM) at an average of $128.61 ($127.00–$129.40, $3.49M total) across 2 trades on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Flammer Martina M.D.
Published Aug 7, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The disclosed event is a pre-arranged open-market sale of INSM shares totaling about $3.49M, with holdings after the transaction of 60,486 shares.

02

Market read

Traders may treat this as routine insider activity unless paired with other negative company-specific developments.

03

What to watch

The article does not state whether the CMO’s sale was part of a larger multi-tranche program, nor does it provide post-sale performance context or any concurrent company news.

Relevance 5/10Novelty 5/10Timing: Filed after-hours on 2026-08-07, reflecting trades dated 2026-08-06.

Background

This is an SEC Form 4 insider transaction disclosure for INSMED Inc, reported by its Chief Medical Officer.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED CMO Flammer Martina sold about $3.49M of INSM shares in open-market trades under a 10b5-1 plan, per Form 4.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment noise rather than a durable repricing.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; insider selling in a single biotech name does not, by itself, reset sector risk appetite.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can still coincide with internal caution about near-term catalysts, so traders may watch for follow-on disclosures.

Key entities

  • INSMED Inc

    US-listed company whose insider transaction is disclosed on Form 4.

  • Flammer Martina M.D.

    Chief Medical Officer who executed the reported open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.